ClinicalTrials.gg

Epidermolysis Bullosa Dystrophica clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 79 studies for Epidermolysis Bullosa Dystrophica across more than 10 countries. 22 are recruiting or about to start. 72 of them are mainly about Epidermolysis Bullosa Dystrophica (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
28
Recruiting
17
Active, not recruiting
8
Status unknown
8
Terminated
8
Not yet recruiting
5

Phase

Phase 2
33
Phase 1
26
Phase 3
11
Early Phase 1
3
Phase 4
2

Where

United States
46
France
16
United Kingdom
6
Germany
4
Spain
4
Austria
4

Who develops what

Add Epidermolysis Bullosa Dystrophica to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 5 with this as their studies’ main aim; 4 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Chiesi Farmaceutici and Energenesis Biomedical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
KB803☆ Track1 live phase-3 study: NCT07016750Krystal Biotech, Inc.
D-Fi☆ Track1 live phase-3 study: NCT06892639Castle Creek Biosciences, LLC.
episalvan☆ Track1 live phase-3 study: NCT06917690Chiesi Farmaceutici S.p.A.
birch triterpenesApproved: US 2023☆ Track1 live phase-3 study: NCT06917690Chiesi Farmaceutici S.p.A.

The 4 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.KB803 · Krystal Biotech, Inc. · Phase 3 main aimNCT07016750 A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa — primary endpoint: To evaluate the safety and tolerability of KB803. · 16 enrolled
  • 15 Mar 2027 est.ENERGI-F703EB Cream · Energenesis Biomedical Co., Ltd. · Phase 2 named, not the main aimNCT07858422 A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa — primary endpoint: Incidence of Local Target Lesion Adverse Events · 24 enrolled
  • Sep 2027 est.D-Fi · Castle Creek Biosciences, LLC. · Phase 3 main aimNCT06892639 Evaluation of D-Fi for the Treatment of Wounds Due to DEB — primary endpoint: The difference in Complete (100%) Wound Closure of the Target Wound Pair at either Week 22 (Visit 6), and Week 24 (Visit 7) or at Week 24 (Visit 7) and Week 26 (Visit 8) as assessed by a Blinded Assessor. · 32 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Epidermolysis Bullosa Dystrophica studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

7studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Who these studies take

Of the 17 Epidermolysis Bullosa Dystrophica studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger. 15 (88%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (12%) take healthy volunteers.

Recruiting studies that take each age, of 17
AgeWomenMen
1015 (88%)15 (88%)
1817 (100%)17 (100%)
3016 (94%)16 (94%)
4015 (88%)15 (88%)
5015 (88%)15 (88%)
6514 (82%)14 (82%)
7514 (82%)14 (82%)
8513 (76%)13 (76%)

Across all 79 studies, recruiting or not: 25% stop at 75 or younger and 25% at 65; 86% take children; 1% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 79. Browse all 79 → or search them.